Likewise, the observed range of IL-6 reduction (–0.9 to –7.6 SD) in our analysis aligns with the spectrum of clinical effects reported for intra-articular administration of mTOR inhibitors in patients with rheumatoid arthritis (40–80% decrease in IL-6 following temsirolimus and related compounds) [11]. The gene discussed is MTOR; the disease is rheumatoid arthritis.